roaccutane 10 mg
roche pharma ag - germania - isotretinoinum - caps. moi - 10mg - preparate de uz sistemic pt. trat. acneei retinoizi pentru tratamentul acneei
sotret 10 mg
terapia s.a. - isotretinoinum - caps. moi - 10mg - produse de uz sistemic pt. trat. acneei retinoizi pentru tratamentul acneei
sotret 20 mg
terapia s.a. - isotretinoinum - caps. moi - 20mg - produse de uz sistemic pt. trat. acneei retinoizi pentru tratamentul acneei
orofar 2 mg/ml+1,5 mg/ml
novartis consumer health gmbh - germania - combinatii - spray bucofaringian,sol. - 2mg/ml+1,5mg/ml - medicamente pentru zona oro-faringiana antiseptice
orofar spray bucofaringian soluție 2 mg/ml + 1,5 mg/ml spray bucofaringian, soluţie
glaxosmithkline consumer healthcare s.r.l. - benzoxonii chloridum + lidocaini hydrochloridum - spray bucofaringian, soluţie - 2 mg/ml + 1,5 mg/ml
roaccutane 10 mg capsule
f.hoffmann-la roche, ltd. - isotretinoinum - capsule - 10 mg
isotretinoin terapia 10 mg
terapia s.a. - isotretinoinum - caps. moi - 10mg - preparate de uz sistemic pt. trat. acneei retinoizi pentru tratamentul acneei
isotretinoin terapia 20 mg
terapia s.a. - isotretinoinum - caps. moi - 20mg - preparate de uz sistemic pt. trat. acneei retinoizi pentru tratamentul acneei
eskazole™ 400 mg comprimate
glaxosmithkline south africa (pty) ltd - albendazolum - comprimate - 400 mg
alunbrig
takeda pharma a/s - brigatinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.